J K Jones

Summary

Affiliation: The Degge Group
Country: USA

Publications

  1. ncbi Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(R), Roche): overview
    Anton Pozniak
    Pharmaceuticals Division, Hoffmann La Roche, Nutley, NJ, USA
    AIDS Res Ther 6:18. 2009
  2. ncbi Pharmacogenetics and pharmacoepidemiology
    J K Jones
    Degge Group, Ltd, Suite 1430, 1616 N Ft Myer Drive, Arlington, VA 22209, USA
    Pharmacoepidemiol Drug Saf 10:457-61. 2001
  3. ncbi The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    J K Jones
    The Degge Group, Ltd, Drug Safety, Arlington, Virginia, USA
    Clin Pharmacol Ther 81:156-8. 2007
  4. ncbi Impact of cisapride label changes on codispensing of contraindicated medications
    Jeff Jianfei Guo
    Degge Group, Ltd, 1616 N Fort Myer Drive, Suite 1430, Arlington, VA 22209, USA
    Pharmacoepidemiol Drug Saf 12:295-301. 2003
  5. ncbi Coprescribing and codispensing of cisapride and contraindicated drugs
    J K Jones
    Director of Research, The Degge Group, Ltd, 1616 N Fort Myer Dr, No. 1430, Arlington, VA 22209, USA
    JAMA 286:1607-9. 2001
  6. ncbi Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada
    Suellen M Curkendall
    Healthcare Data Analysis, Vienna, VA 22180, USA
    J Clin Psychiatry 65:715-20. 2004
  7. ncbi Hospitalized cardiovascular diseases in neovascular age-related macular degeneration
    Bao Anh Nguyen-Khoa
    The Degge Group, Ltd, Arlington, Virginia, USA
    Arch Ophthalmol 126:1280-6. 2008
  8. ncbi Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
    Suellen M Curkendall
    Cerner Health Insights, Vienna, VA 22182, USA
    Ann Epidemiol 16:63-70. 2006
  9. ncbi Epidemiologic study of smell disturbance in 2 medical insurance claims populations
    Bao Anh Nguyen-Khoa
    The Degge Group Ltd, 1616 Fort Myer Dr, Ste 1430, Arlington, VA 22209, USA
    Arch Otolaryngol Head Neck Surg 133:748-57. 2007
  10. ncbi Drug safety relies on YOU, the healthcare professional, to find and report new serious adverse reactions
    Judith K Jones
    Medscape J Med 10:95. 2008

Research Grants

  1. KNOWLEDGE EMPOWERMENT FOR YOUTH WITH SOLID TUMORS
    Judith Jones; Fiscal Year: 2004

Collaborators

  • Suellen M Curkendall
  • Stephen Bartels
  • S D Horn
  • Felix M Arellano
  • Bao Anh Nguyen-Khoa
  • Cynthia de Luise
  • Anton Pozniak
  • Stephen P Motsko
  • William N Kelly
  • Ann Strauss
  • Jeff Jianfei Guo
  • Miklos Salgo
  • Peter Larson
  • David Tweats
  • Kui Huang
  • Frank Williams
  • Rachel McLeay
  • Stephen B Freedman
  • Nicholas Moore
  • Alina M Fernandez
  • Joanne Barnes
  • Thierry Trenque
  • Ulf Bergman
  • Rosie H Stather
  • William G Troutman
  • Robert P Wise
  • Eugene van Puijenbroek
  • I Ralph Edwards
  • David I Goldsmith
  • Linda M Nelsen
  • Bengt-Erik Wiholm
  • A Lawrence Gould
  • Daniel Fife
  • Earl Goehring
  • Dewei She

Detail Information

Publications16

  1. ncbi Elevated ethyl methanesulfonate (EMS) in nelfinavir mesylate (Viracept(R), Roche): overview
    Anton Pozniak
    Pharmaceuticals Division, Hoffmann La Roche, Nutley, NJ, USA
    AIDS Res Ther 6:18. 2009
    ..These findings are potentially relevant to >40 marketed drugs that are mesylate salts...
  2. ncbi Pharmacogenetics and pharmacoepidemiology
    J K Jones
    Degge Group, Ltd, Suite 1430, 1616 N Ft Myer Drive, Arlington, VA 22209, USA
    Pharmacoepidemiol Drug Saf 10:457-61. 2001
    ..Social, methodologic, and ethical issues relate to any protocol using serum and tissue, and indicate a need for broad educational efforts. We must set guidelines as pharmacogenetics research becomes a dimension of pharmacoepidemiology...
  3. ncbi The Institute of Medicine's report on drug safety: constructive and ambitious, but does it go far enough?
    J K Jones
    The Degge Group, Ltd, Drug Safety, Arlington, Virginia, USA
    Clin Pharmacol Ther 81:156-8. 2007
    ..In response, the FDA's Center for Drug Evaluation and Research (CDER) asked the Institute of Medicine (IOM) to examine the current systems for ensuring drug safety and recommend specific actions and improvements...
  4. ncbi Impact of cisapride label changes on codispensing of contraindicated medications
    Jeff Jianfei Guo
    Degge Group, Ltd, 1616 N Fort Myer Drive, Suite 1430, Arlington, VA 22209, USA
    Pharmacoepidemiol Drug Saf 12:295-301. 2003
    ..To quantify the impact of the first three label changes and 'Dear Doctor' letters as sole interventions, sent to prescribers and pharmacists, on the prescribing and dispensing of cisapride and contraindicated drugs...
  5. ncbi Coprescribing and codispensing of cisapride and contraindicated drugs
    J K Jones
    Director of Research, The Degge Group, Ltd, 1616 N Fort Myer Dr, No. 1430, Arlington, VA 22209, USA
    JAMA 286:1607-9. 2001
    ..The pharmacy may be an important and underutilized intervention point to prevent contraindicated drugs from being used together...
  6. ncbi Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada
    Suellen M Curkendall
    Healthcare Data Analysis, Vienna, VA 22180, USA
    J Clin Psychiatry 65:715-20. 2004
    ..However, population-based data on the prevalence, incidence, and mortality of cardiovascular disease are needed...
  7. ncbi Hospitalized cardiovascular diseases in neovascular age-related macular degeneration
    Bao Anh Nguyen-Khoa
    The Degge Group, Ltd, Arlington, Virginia, USA
    Arch Ophthalmol 126:1280-6. 2008
    ..To compare the incidence rate of hospitalized myocardial infarctions (MIs) and cerebrovascular accidents (CVAs) in subjects with and without neovascular age-related macular degeneration (AMD)...
  8. ncbi Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients
    Suellen M Curkendall
    Cerner Health Insights, Vienna, VA 22182, USA
    Ann Epidemiol 16:63-70. 2006
    ..To measure prevalence, incidence, and mortality of cardiovascular outcomes among persons with chronic obstructive pulmonary disease (COPD) and to assess the extent these outcomes differ from persons without COPD...
  9. ncbi Epidemiologic study of smell disturbance in 2 medical insurance claims populations
    Bao Anh Nguyen-Khoa
    The Degge Group Ltd, 1616 Fort Myer Dr, Ste 1430, Arlington, VA 22209, USA
    Arch Otolaryngol Head Neck Surg 133:748-57. 2007
    ..To report the rates of medical claims for sense of smell disturbance (SD) and their association with diseases and medications in a managed care population...
  10. ncbi Drug safety relies on YOU, the healthcare professional, to find and report new serious adverse reactions
    Judith K Jones
    Medscape J Med 10:95. 2008
  11. ncbi Is there an association between hypothyroidism and open-angle glaucoma in an elderly population? An epidemiologic study
    Stephen P Motsko
    Degge Group, Ltd, Arlington, Virginia 22209, USA
    Ophthalmology 115:1581-4. 2008
    ..The purpose of this study was to assess the hypothesized association between preexisting hypothyroidism and development of OAG in a population-based setting...
  12. ncbi Guidelines for submitting adverse event reports for publication
    William N Kelly
    William N Kelly Consulting, Inc, Oldsmar, Florida 34677, USA
    Pharmacoepidemiol Drug Saf 16:581-7. 2007
    ..They also encourage schools of medicine, pharmacy, and nursing to incorporate them into the relevant curricula that address the detection, evaluation, and reporting of suspected drug or other medical product adverse events...
  13. ncbi Agitation and depression in frail nursing home elderly patients with dementia: treatment characteristics and service use
    Stephen J Bartels
    Aging Services Research, New Hampshire Dartmouth Psychiatric Research Center, Department of Psychiatry, Dartmouth Medical School, Lebanon, NH 03766, USA
    Am J Geriatr Psychiatry 11:231-8. 2003
    ..The authors describe characteristics, treatment, and acute service use associated with agitation and depression in dementia...
  14. ncbi Spontaneous reports cannot serve as a basis for comparison of two drugs
    Judith K Jones
    Am J Cardiol 92:1141-2. 2003
  15. ncbi Public-released version of the Adverse Event Reporting System (AERS) database
    Ann Strauss
    Clin Ther 27:355-7; author reply 357-9. 2005
  16. ncbi Chronic obstructive pulmonary disease severity and cardiovascular outcomes
    Suellen M Curkendall
    Cerner LifeSciences, 1953 Gallows Road, Suite 570, Vienna, VA 22182, USA
    Eur J Epidemiol 21:803-13. 2006
    ..To identify predictors of chronic obstructive pulmonary disease (COPD) severity and assess the relation between COPD severity and risk of cardiovascular outcomes...

Research Grants1

  1. KNOWLEDGE EMPOWERMENT FOR YOUTH WITH SOLID TUMORS
    Judith Jones; Fiscal Year: 2004
    ..Once developed, the CD-ROM will be marketed so that it will be available to all adolescents with solid tumors. ..